Idiopathic pulmonary hemosiderosis
- Hemosiderosis, pulmonary, with deficiency of gamma-a globulin
- Alveolar hypoventilation syndrome
- Pulmonary hemosiderosis
Your QuestionWhat is the prognosis for individuals affected by idiopathic pulmonary hemosiderosis? Will a cure become available? Can the disease become terminal?
We have identified the following information that we hope you find helpful. If you still have questions, please contact us.
Questions on this page
More detailed information about the treatment of idiopathic pulmonary hemosiderosis can be accessed through eMedicine. Click on the following links to learn more about Treatment & Management and Medications.
The clinical course of idiopathic pulmonary hemosiderosis varies widely. Overall, the prognosis is poor, with a mean survival of 2.5 to 5 years following diagnosis. Death may result from acute massive hemorrhage or from progressive pulmonary insufficiency and right heart failure. Treatment does not appear to greatly improve survival. One study noted the following:
- The severity of the disease at onset did not correlate with the outcome,
- Females survive longer than males,
- Younger individuals exhibit a less favorable prognosis, and
- Common therapies did not affect outcome.
Another study of children with idiopathic pulmonary hemosiderosis found that the presence of antineutrophil cytoplasmic antibodies or other autoantibodies translated to a poor prognosis.
- Napchan GD, Talmaciu I. Hemosiderosis. eMedicine. 2009; http://emedicine.medscape.com/article/1002002-overview. Accessed 7/6/2011.